Managing Director & Senior Partner
Paris
More than 2 billion people in low- and middle-income countries (LMICs) lack access to crucial medicines. Over the next four decades, serious health-related suffering is expected to rise three times faster in low-income countries than high-income countries.
Although biopharma companies are strategizing new ways to enhance access to medicines, some 70% of R&D priorities for LMICs, including maternal conditions and infectious diseases, remain unaddressed. (See the exhibit.) Currently, drugs are six times more likely to be registered for regulatory approval in upper-middle-income countries than in LMICs.
But LMICs represent a large, untapped market for biopharma companies seeking growth opportunities. For example, the global insulin market is worth approximately $25 billion to $35 billion per year, yet approximately half of patients who need it cannot obtain it. If companies could serve just 10% of this population at less than one-third of the average price, insulin manufacturers would yield an additional $1 billion.
By leveraging innovative business models and partnerships with the right players, companies could reach these markets at no extra cost, delivering a win-win for biopharma and patients in need. So what are the barriers to people in LMICs receiving these vital medicines?
Four barriers stand in the way, as seen in the slideshow:
Barriers to Adaptation. Typically, medical products are not designed and developed with the needs of the LMIC patients or the constraints of their health systems in mind. For example, certain drugs may require diagnostics to be performed by a specialized doctor—a scarce resource in LMICs. If products were designed in such a way that health care workers could perform the diagnostics, many more patients could gain access to the drug. This worked well for HIV when the strategy moved to a universal “test and treat” approach (testing and immediately treating HIV positive individuals regardless of stage of infection) in combination with a standardized drug regimen (using predefined treatments versus customized ones).
Barriers to Availability. Drugs may not be available (or not sufficiently available) in LMICs because they lack regulatory approval, there are limited numbers of manufacturers, or production capacity is constrained.
Barriers to Affordability. Patients or health systems cannot afford the costs associated with the medicines.
Barriers to Adoption. Adoption can be hindered because of health care worker shortages, national treatment guidelines that don’t include the drug, or limited awareness of the product’s availability. While high-income countries may also face barriers to adoption (as with vaccine hesitancy, for example), the health systems have very effective mechanisms to communicate with and educate patients whereas LMICs need to communicate through communities.
What works in high-income countries doesn’t usually work in the same way in LMICs because they have so many fundamental differences, so strategies need to be adapted accordingly.
When stakeholders work together to overcome these barriers, they save lives. With HIV, for example, the global community, public sector, private sector, governments, and civil society, among others, came together to:
For malaria, the global community, public sector, private sector, governments, civil society, and other stakeholders worked together to:
Biopharma leaders can take four actions to seize the opportunity within health equity:
The authors would like to thank Ben Desmond, Akos Szabo, Guervan Adnet, and Robin Lavers for their contributions to this article.
ABOUT BOSTON CONSULTING GROUP
Boston Consulting Group partners with leaders in business and society to tackle their most important challenges and capture their greatest opportunities. BCG was the pioneer in business strategy when it was founded in 1963. Today, we work closely with clients to embrace a transformational approach aimed at benefiting all stakeholders—empowering organizations to grow, build sustainable competitive advantage, and drive positive societal impact.
Our diverse, global teams bring deep industry and functional expertise and a range of perspectives that question the status quo and spark change. BCG delivers solutions through leading-edge management consulting, technology and design, and corporate and digital ventures. We work in a uniquely collaborative model across the firm and throughout all levels of the client organization, fueled by the goal of helping our clients thrive and enabling them to make the world a better place.
© Boston Consulting Group 2024. All rights reserved.
For information or permission to reprint, please contact BCG at permissions@bcg.com. To find the latest BCG content and register to receive e-alerts on this topic or others, please visit bcg.com. Follow Boston Consulting Group on Facebook and X (formerly Twitter).